SARS-CoV-2 Vaccine Safety and Efficacy Studies

The global response to the COVID-19 pandemic has centred on the rapid development, testing and deployment of vaccines designed to prevent severe acute respiratory syndrome coronavirus 2 infection and its complications. Clinical trials have employed diverse platforms—including mRNA, adenoviral vectors and inactivated whole virus—to elicit protective immune responses. Phase 1 and 2 studies established immunogenicity profiles and optimal dosing regimens, while large-scale phase 3 randomised controlled trials have measured vaccine efficacy against symptomatic disease, hospitalisation and death. Across platforms, efficacy estimates have ranged from moderate protection against infection to very high efficacy in preventing severe outcomes. Safety evaluations indicate that most vaccines are well tolerated, with transient local and systemic reactions such as injection-site pain, fever and fatigue. Rare but serious adverse events, monitored through post-licensure surveillance, have informed risk–benefit assessments. Studies of emerging viral variants have further assessed neutralising antibody titres and real-world effectiveness, demonstrating modest reductions in protection against certain lineages but sustained defence against severe disease. Continued monitoring of immunogenicity, waning immunity and booster strategies underpins global vaccination policies and guides adjustments to address demographic and geographic disparities in vaccine performance.

Research from Nature Portfolio

No recent Nature Portfolio content available.

SARS-CoV-2 Vaccine Safety and Efficacy Studies publication trend

The graph below shows the total number of articles in sars-cov-2 vaccine safety and efficacy studies across all publications each year (not limited to Nature Index journals).

Technical terms

Randomised controlled trial: A study design in which participants are randomly assigned to vaccine or control groups to evaluate efficacy and safety under blinded conditions.

Vaccine efficacy: The relative reduction in disease risk among vaccinated individuals compared with unvaccinated controls, typically expressed as a percentage.

Neutralising antibody: An antibody capable of binding to a virus and inhibiting its entry into host cells, measured in vitro to infer protective immunity.

Reactogenicity: The propensity of a vaccine to produce common, transient adverse reactions, such as fever or injection-site pain, reflecting immune activation.

References

1. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet (2020).
2. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet (2021).
3. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines (2021).